Clinical trials
Crohn's Disease, Active clinical trials
Below are recruiting crohn's disease, active clinical trials, each written for real people, not researchers. We’re tracking 195 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06819878RecruitingPhase 3
Afimkibart for moderate to severe Crohn's disease
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
Dothan, AlabamaAges 16–80 - NCT07636304Enrolling by invitationEarly Phase 1
Brain stimulation for inflammatory bowel disease remission
This study tests whether a non-invasive device that stimulates the vagus nerve (a major nerve in your neck) can affect brain function in people whose IBD is in remission. Researchers want to understand if this stimulation might help reduce inflammation or improve symptoms in the future.
Gdansk, Pomeranian VoivodeshipAges 18 years+ - NCT07298421RecruitingPhase 3
Testing afimkibart for children with Crohn's disease
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
New York, New YorkAges 2–17 - NCT06819891RecruitingPhase 3
Study of afimkibart for active Crohn's disease
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
Dothan, AlabamaAges 16–80 - NCT06902987RecruitingPhase 1
Upatinib for anal fistulas in Crohn's disease
This trial tests whether upatinib can help heal active anal fistulas in people with moderate to severe Crohn's disease. If you have an anal fistula that is causing pain or drainage, this study may offer a new treatment option.
Guangzhou, GuangdongAges 18–70 - NCT07499232RecruitingPhase 3
Guselkumab vs Risankizumab for Crohn's disease
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Dothan, AlabamaAges 18 years+ - NCT07577843RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe Crohn's disease
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
Anaheim, CaliforniaAges 18 years+ - NCT07196722RecruitingPhase 2/Phase 3
Testing icotrokinra for moderate to severe Crohn's disease
This study tests a new medicine called icotrokinra for people with moderate to severe Crohn's disease who have not responded well to other treatments. It aims to see if icotrokinra can help reduce symptoms and improve gut health.
Chandler, ArizonaAges 18 years+ - NCT07170462RecruitingEarly Phase 1
Cranberry and Gut Health in Crohn's Disease
This trial tests whether taking a daily cranberry supplement can improve gut health and quality of life in people with Crohn's disease. It may help those whose current treatment is stable but still have bothersome symptoms.
Worcester, MassachusettsAges 18–65 - NCT03915262Recruiting
Active Crohn’s patients with possible pancreas enzyme problems
This study looks at how often people with active Crohn’s disease also have trouble digesting food because the pancreas may not release enough enzymes (exocrine pancreatic insufficiency). It may help doctors better recognize this hidden problem in people whose Crohn’s is currently active.
Pierre-BéniteAges 18 years+ - NCT04187820Recruiting
Acupuncture for mild to moderate Crohn’s flare
This trial tests whether acupuncture can help calm an active Crohn’s disease flare that is mild to moderate. It may be an option if standard Crohn’s medicines like steroids, immunosuppressors, and anti-TNF drugs are not working for you or you can’t tolerate them.
Shanghai, Shanghai MunicipalityAges 16–70 - NCT04777656RecruitingPhase 3
Crohn’s exclusion diet plus usual care for kids
This study tests whether a specific “exclusion diet” (removing certain foods) added to standard treatment can better control unstable Crohn’s disease in children. It may help reduce inflammation and flare-ups when symptoms are not controlled by usual medicines.
BronAges 6–17 - NCT05321758Recruiting
Stool transplant as first treatment for kids with Crohn’s
This study tests whether transferring healthy gut bacteria from stool into the colon can work as a first treatment for children newly diagnosed with mild-to-moderate Crohn’s disease. It may help reduce inflammation and improve symptoms, and it requires regular colonoscopy to monitor progress.
Wuhan, HubeiAges 2–16 - NCT05332639Recruiting
Risk tracking test for Crohn’s disease in teens
This study checks whether a personalized tool can estimate someone’s risk for Crohn’s disease before symptoms start. It may help families learn early risk and decide on next steps sooner.
Boston, MassachusettsAges 14 years+ - NCT05835973Recruiting
Study of sleep changes in people with inflammatory bowel disease
This study looks at how sleep patterns change in adults with inflammatory bowel disease (IBD) who are currently in remission. It may help researchers understand sleep issues in IBD and identify ways to improve care during symptom-free periods.
Clermont-FerrandAges 18–65 - NCT05923073RecruitingPhase 3
Guselkumab for children with active Crohn’s disease
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
Los Angeles, CaliforniaAges 2–17 - NCT05928039RecruitingPhase 4
Choosing the best first biologic for Crohn’s in the ileum
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
Calgary, AlbertaAges 18 years+ - NCT05995353RecruitingPhase 3
Risankizumab for children with moderate to severe Crohn's
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
Phoenix, ArizonaAges 2–17 - NCT06023030Recruiting
Observing how upadacitinib works for Crohn's disease in Japan
This study is for people with moderate to severe Crohn's disease who are starting a medication called upadacitinib. Researchers will watch how the disease changes over time and check for any side effects. It's an observational study, meaning you'll keep getting your regular treatment.
Anjo-shi, Aichi-kenAges 15 years+ - NCT06051253RecruitingPhase 4
Personalized infliximab dosing for active Crohn's fistulas
This study tests whether adjusting the dose of infliximab (a biologic medicine given by IV) based on drug levels in your blood works better for treating draining fistulas caused by Crohn's disease. It is for people who have not tried other biologics and whose fistulas have not healed with usual treatments.
SeoulAges 19–80 - NCT06059989RecruitingPhase 3
Testing a new form of infliximab for Crohn's disease
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
Amsterdam, North HollandAges 18–80 - NCT06257706RecruitingPhase 4
Healing the bowel wall in Crohn's disease with vedolizumab
This study tests whether a medicine called vedolizumab can help heal all layers of the bowel wall in Crohn's disease. It uses a special ultrasound to see inside the bowel, aiming for deeper healing than usual.
Los Angeles, CaliforniaAges 18–80 - NCT06274554RecruitingPhase 3
Testing Antifungal Therapy for Crohn's Disease
This study tests whether adding an antifungal drug (fluconazole) to standard Crohn's disease treatment helps improve symptoms. It's for people with mild to moderate Crohn's who have not used antifungal medications recently.
New York, New YorkAges 18 years+ - NCT06332534RecruitingPhase 3
Upadacitinib in children with moderate to severe Crohn's disease
This study tests an oral pill called upadacitinib for children with moderate to severe Crohn's disease that hasn't responded well to other treatments. It aims to see if the medicine can reduce inflammation and improve symptoms safely.
Oakland, CaliforniaAges 2–17
Hear when a new Crohn's Disease, Active trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for crohn's disease, active?
- Yes. Clin2 currently lists 195 recruiting crohn's disease, active studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a crohn's disease, active trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a crohn's disease, active trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.